Loomis, Sayles & Company
PCRX icon

Loomis, Sayles & Company’s Pacira BioSciences PCRX Stock Holding History

Loomis, Sayles & Company’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-412,325
Closed -$11.8M – 733
2024
Q2 		$11.8M Buy
412,325
+33,692
+9% +$959K 0.02% 329
2024
Q1 		$11.1M Buy
378,633
+51,841
+16% +$1.59M 0.02% 341
2023
Q4 		$11M Sell
326,792
-48,188
-13% -$1.41M 0.02% 322
2023
Q3 		$11.5M Buy
374,980
+34,811
+10% +$1.25M 0.02% 317
2023
Q2 		$13.6M Buy
340,169
+66,353
+24% +$2.74M 0.02% 298
2023
Q1 		$11.2M Sell
273,816
-1,198,102
-81% -$47.7M 0.02% 317
2022
Q4 		$56.8M Buy
1,471,918
+33,177
+2% +$1.61M 0.11% 95
2022
Q3 		$76.5M Buy
1,438,741
+152,912
+12% +$8.5M 0.16% 75
2022
Q2 		$75M Sell
1,285,829
-7,871
-0.6% -$516K 0.14% 74
2022
Q1 		$98.7M Buy
1,293,700
+102,986
+9% +$6.86M 0.13% 66
2021
Q4 		$71.6M Buy
1,190,714
+38,867
+3% +$2.14M 0.09% 103
2021
Q3 		$64.5M Buy
1,151,847
+25,648
+2% +$1.48M 0.08% 109
2021
Q2 		$68.3M Sell
1,126,199
-6,384
-0.6% -$404K 0.08% 105
2021
Q1 		$79.4M Sell
1,132,583
-1,770
-0.2% -$126K 0.1% 86
2020
Q4 		$67.9M Buy
1,134,353
+292,253
+35% +$17.1M 0.09% 92
2020
Q3 		$50.6M Buy
842,100
+15,868
+2% +$922K 0.07% 108
2020
Q2 		$43.4M Buy
826,232
+71,236
+9% +$2.98M 0.07% 108
2020
Q1 		$25.3M Buy
754,996
+230,403
+44% +$9.57M 0.05% 136
2019
Q4 		$23.8M Sell
524,593
-862
-0.2% -$36.6K 0.04% 187
2019
Q3 		$20M Buy
+525,455
New +$21M 0.04% 211
2016
Q4 		– Sell
-62
Closed -$2K – 1084
2016
Q3 		$2K Hold
62
– – ﹤0.01% 967
2016
Q2 		$2K Sell
62
-49
-44% -$2.41K ﹤0.01% 950
2016
Q1 		$6K Buy
111
+74
+200% +$4.33K ﹤0.01% 922
2015
Q4 		$3K Buy
+37
New +$2.1K ﹤0.01% 968
2014
Q4 		– Sell
-140,309
Closed -$13.6M – 752
2014
Q3 		$13.6M Sell
140,309
-38,922
-22% -$3.79M 0.04% 432
2014
Q2 		$16.5M Sell
179,231
-63,285
-26% -$4.82M 0.05% 413
2014
Q1 		$17M Sell
242,516
-30,899
-11% -$2.1M 0.05% 407
2013
Q4 		$15.7M Sell
273,415
-125,669
-31% -$6.61M 0.05% 421
2013
Q3 		$19.2M Sell
399,084
-85,752
-18% -$3.12M 0.06% 341
2013
Q2 		$14.1K Buy
+484,836
New +$14M 0.05% 406

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Loomis, Sayles & Company's PCRX Position: Q3 2024 in Review

Loomis, Sayles & Company sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 412,325 shares — an estimated $11.8M sold.

Loomis, Sayles & Company first reported a position in PCRX in Q2 2013 and held it in 30 quarters. The position peaked at $98.7M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Loomis, Sayles & Company reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 412,325 Pacira BioSciences shares in Q3 2024, an estimated $11.8M.
  • Loomis, Sayles & Company first reported a position in Pacira BioSciences in Q2 2013 and held it in 30 quarters.
  • Loomis, Sayles & Company's Pacira BioSciences position peaked at $98.7M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Loomis, Sayles & Company's 13F filing for Q3 2024, filed 13 Nov 2024.